Clinical trials: Severe Trauma
Posttraumatic Stress Disorder
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with at least severe PTSD.
- Trial name
- NCT03485287
- Testing
- Midomafetamine HCl, Manualized therapy
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Resilient Pharmaceuticals
Trauma, Hemorrhagic Shock
Phase 2c Dose Comparison Study of MP4OX in Trauma
MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to improve perfusion and target delivery of oxygen…
- Conditions
- Trauma, Hemorrhagic Shock, Lactic Acidosis
- Trial name
- NCT01973504
- Testing
- MP4OX, Control
- Where
- 31 sites in Australia, Belgium and 9 more
- Sponsor
- Sangart
Arthroscopic Surgical Treatment of High-grade (>50%) Partialthickness
Treatment of Partial-Thickness Rotator Cuff Tears
The goal of this clinical trial is to demonstrate that REGENETEN is superior to standard repair techniques when surgically treating high-grade (>50%) partial-thickness tears.
- Trial name
- REGEN PUB 2018 (NCT03734536)
- Testing
- REGENETEN™ Bioinductive Implant, Arthroscopic repair of the high-grade (>50%) partial-thickness
- Where
- 10 sites in United States
- Volunteers
- 168 people
- Sponsor
- Smith & Nephew, Inc.
Sprain
Efficacy Study of a Sensory Feedback Knee Orthosis in Patients Suffering From Unoperated Severe Knee Sprain
Ortheses are commonly used for the repair of damage to the musculoskeletal system. However, immobility, by itself, causes serious side effects that require long and costly rehabilitation.
- Trial name
- ORTHOSENS (NCT01508728)
- Testing
- ORTHOSENS orthosis
- Where
- 3 sites in France
- Volunteers
- 104 people
- Sponsor
- Thuasne
Hip Injuries, Fractures, Hip
Mitigation of Major Hip Injury Due to Fall With a Smart Belt
Multi-center, comparative, non-significant risk adaptive study with retrospective controls. After providing informed consent and being screened for eligibility, intervention subjects will be prescribed and provided an…
- Conditions
- Hip Injuries, Fractures, Hip, Fall Injury, Fall Risk
- Trial name
- NCT05245097
- Testing
- Tango Belt, Standard of Care (SOC)
- Where
- 10 sites in United States
- Volunteers
- 471 people
- Sponsor
- ActiveProtective Technologies, Inc
Acute Kidney Injury
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at…
- Trial name
- NCT06602453
- Testing
- GDC-8264
- Where
- 34 sites in United States, Australia and 10 more
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Traumatic Brain Injury
Study of Oxycyte in Severe Closed Head Injury
Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in…
- Trial name
- NCT00174980
- Testing
- Oxycyte
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tenax Therapeutics, Inc.
Traumatic Brain Injury, Cerebral Edema
Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
The purpose of this study is to investigate the clinical improvement measured by the Glasgow Outcome Scale Extended (GOS-E) with ABX-101 compared with Placebo intramuscular injection in participants with moderate to severe TBI.
- Trial name
- NCT06096415
- Testing
- ABX-101 1mg, ABX-101 2mg
- Volunteers
- 45 people
- Sponsor
- Abalonex, LLC
Coronavirus Infection
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19…
- Trial name
- NCT04326426
- Testing
- Tradipitant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Vanda Pharmaceuticals
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Acute Kidney Injury
Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery
The purpose of this clinical trial is to assess the efficacy and safety of cell therapy with modified leukocyte cells from the participant himself/herself versus placebo in participants who develop Acute Kidney Injury (AKI)…
- Trial name
- NCT07052513
- Testing
- M2RLAB 001
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- M2RLAB SL
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
PTSD - Post Traumatic Stress Disorder
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
The goal of the REVEAL PTSD study is to test how well the Senseye DT works as a diagnostic test for Post-traumatic Stress Disorder (PTSD) in adults 18 and older who are experiencing one or more symptoms that might be related to…
- Trial name
- NCT07280065
- Testing
- Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version
- Where
- 6 sites in United States, Australia
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
Burns
Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries
After severe burn injury, the full-thickness burn areas are excised (in the first week) and then temporarily covered with allograft (cryogenic preserved cadaver skin).
- Trial name
- NCT00366041
- Testing
- Dermal substrate cellularised LG002 (10x10cm), Dermal substrate uncellularised LG002 (10x10 cm)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Laboratoires Genévrier
Oral Mucositis, Quality of Life
Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- STOPOMP (NCT05635929)
- Testing
- XCM-OM118 Composition comprising olive oil, betaine and xylitol
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Mucosa Innovations, S.L.
ARDS (Acute Respiratory Distress Syndrome)
Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07706855
- Testing
- GKL-006RTU injection
- Volunteers
- 52 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Diabetic Foot, Arterial Occlusive Disease
Urokinase Therapy in Diabetic Foot Syndrome
The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000 000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in patients with diabetic foot syndrome.
- Conditions
- Diabetic Foot, Arterial Occlusive Disease, Ischemia
- Trial name
- NCT00537498
- Testing
- Urokinase
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- medac GmbH
Hypofibrinogenemia, Hemorrhage
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
The objective of this multicenter, single-arm, observational study is to determine the feasibility and effectiveness of early administration of FDA-approved, pre-thawed Pathogen Reduced Cryoprecipitated Fibrinogen Complex…
- Conditions
- Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
- Trial name
- CRYO-FIRST (NCT07218185)
- Testing
- Pathogen Reduced Cryoprecipitated Fibrinogen Complex
- Where
- 4 sites in United States
- Volunteers
- 320 people
- Sponsor
- Cerus Corporation